Literature DB >> 2472229

Protooncogene methylation and expression in regenerating liver and preneoplastic liver nodules induced in the rat by diethylnitrosamine: effect of variations of S-adenosylmethionine:S-adenosylhomocysteine ratio.

R Garcea1, L Daino, R Pascale, M M Simile, M Puddu, M E Ruggiu, M A Seddaiu, G Satta, M J Sequenza, F Feo.   

Abstract

S-adenosylmethionine:S-adenosylhomocysteine (SAM/SAH) ratio, 5-methylcytosine (5mC) DNA content, and methylation and expression of c-myc, c-Ha-ras and c-Ki-ras have been studied in liver nodules, induced by diethylnitrosamine according to the 'resistant hepatocyte' model, and in regenerating liver (RL) between 0.5 and 72 h after partial hepatectomy (PH). Nodules, 11, 13 and 21 weeks after initiation, grew actively, showed a low tendency to remodel (persistent nodules), and did not exhibit carcinomatous changes. They underwent extensive remodeling after a 1-week SAM treatment (64 mumol/kg/day), and decreased in size and number after a 3-11-week treatment. A low SAM/SAH ratio was coupled, in nodules, with a high labeling index (LI), 2-fold fall in 5mC DNA content, increase in c-myc, c-Ha-ras and c-Ki-ras expression and hypomethylation of CCGG sequences in the DNA hybridizing with the three protooncogenes. In RL a low SAM/SAH ratio, overall DNA hypomethylation and enhanced c-myc expression were first observed 0.5 h after PH, reached a peak at 5 h and progressively returned to pre-PH levels later on. Maximum expression of c-Ha-ras and c-Ki-ras occurred 24-30 h after PH, roughly coincident with the LI peak. However, no great modifications of the methylation pattern of protooncogene CCGG sequence occurred at any time after PH, indicating the presence of hypomethylated genes and/or DNA sequences different from those investigated in this paper. SAM injection to nodule-bearing rats, for 1-11 weeks before killing, and to hepatectomized rats, 2 days before PH and then up to killing, largely prevented decrease in the SAM/SAH ratio and overall DNA methylation and inhibited LI and protooncogene expression. In nodules these effects were proportional to the treatment length and coupled with methylation of CpG residues in the CCGG sequence of the three protooncogenes studied. SAM treatment left the methylation pattern of these genes unchanged in RL. Kinetics of increase in protooncogene expression suggest a role in the regulation of cell cycle in RL. However, decrease in the SAM/SAH ratio, protooncogene hypomethylation and enhanced expression are apparently stable in nodules 11-21 weeks after initiation and could be implicated in continuous nodule growth and progression. Control of DNA methylation and gene expression by exogenous SAM could be a mechanism of the SAM anti-progression effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472229     DOI: 10.1093/carcin/10.7.1183

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  18 in total

1.  MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes.

Authors:  Maria M Simile; Graziella Peitta; Maria L Tomasi; Stefania Brozzetti; Claudio F Feo; Alberto Porcu; Antonio Cigliano; Diego F Calvisi; Francesco Feo; Rosa M Pascale
Journal:  Oncotarget       Date:  2019-04-19

Review 2.  Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome.

Authors:  Michael J Hitchler; Frederick E Domann
Journal:  Free Radic Biol Med       Date:  2012-09-26       Impact factor: 7.376

Review 3.  Deregulation of methionine metabolism as determinant of progression and prognosis of hepatocellular carcinoma.

Authors:  Rosa M Pascale; Claudio F Feo; Diego F Calvisi; Francesco Feo
Journal:  Transl Gastroenterol Hepatol       Date:  2018-06-29

4.  Evidence for LKB1/AMP-activated protein kinase/ endothelial nitric oxide synthase cascade regulated by hepatocyte growth factor, S-adenosylmethionine, and nitric oxide in hepatocyte proliferation.

Authors:  Mercedes Vázquez-Chantada; Usue Ariz; Marta Varela-Rey; Nieves Embade; Nuria Martínez-Lopez; David Fernández-Ramos; Laura Gómez-Santos; Santiago Lamas; Shelly C Lu; M Luz Martínez-Chantar; José M Mato
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

5.  S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model.

Authors:  Shelly C Lu; Komal Ramani; Xiaopeng Ou; Mark Lin; Victor Yu; Kwangsuk Ko; Ryan Park; Teodoro Bottiglieri; Hidekazu Tsukamoto; Gary Kanel; Samuel W French; José M Mato; Rex Moats; Edward Grant
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

6.  S-adenosylmethionine regulates apurinic/apyrimidinic endonuclease 1 stability: implication in hepatocarcinogenesis.

Authors:  Maria Lauda Tomasi; Ainhoa Iglesias-Ara; Heping Yang; Komal Ramani; Francesco Feo; Maria Rosa Pascale; M Luz Martínez-Chantar; José M Mato; Shelly C Lu
Journal:  Gastroenterology       Date:  2008-09-25       Impact factor: 22.682

7.  Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Authors:  Sai Murali Krishna Pulukuri; Norman Estes; Jitendra Patel; Jasti S Rao
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis.

Authors:  Francesco Feo; Maddalena Frau; Rosa-Maria Pascale
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

Review 9.  Metabolic defects provide a spark for the epigenetic switch in cancer.

Authors:  Michael J Hitchler; Frederick E Domann
Journal:  Free Radic Biol Med       Date:  2009-04-10       Impact factor: 7.376

10.  Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice.

Authors:  M Luz Martínez-Chantar; Mercedes Vázquez-Chantada; Usue Ariz; Nuria Martínez; Marta Varela; Zigmund Luka; Antonieta Capdevila; Juan Rodríguez; Ana M Aransay; Rune Matthiesen; Heping Yang; Diego F Calvisi; Manel Esteller; Mario Fraga; Shelly C Lu; Conrad Wagner; José M Mato
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.